Health care innovations are happening at a rapid pace. The digital revolution continues to push boundaries on how healthcare is being delivered! Right now, many ambitious startups continue to shape up the industry on a global scale moving forward. And one such startup is uMed, a London-based research technology company. 

Raised £3.7 million funding

Recently, uMed raised £3.7 million from venture capital investors including AlbionVC, Delin Ventures, and Playfair Capital, along with Silicon Valley’s 11.2 Capital. 

How will the funding be used?

The company will be using the fund to help healthcare providers in the UK and US, including GPs, hospitals, and health specialists, the tools to run patient research more efficiently while safeguarding patient data and ensuring regulatory compliance.

Used in RAPTOR-C19 study

Based out of London, uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolised patient registries. 

It is delivering its technology to several clinical research studies including the University of Oxford-led RAPTOR-C19 study. It’s worth mentioning here that RAPTOR-C19 is comparing the accuracy of different rapid tests for Covid-19 among patients in community settings, such as GP surgeries.

Ensures efficient execution

The uMed platform provides the necessary functionality required to digitally target and engage patients for this study. It enables e-consent and the automated capture of structured outcomes remotely which are linked back to the data from each patient record. This ensures the efficient execution of the study across a large number of sites, and allow healthcare providers to participate in many more of these studies.

Embedded in 160 primary care sites in the UK

Dr Matt Wilson, uMed’s founder and CEO, developer the platform to connect life science researchers with healthcare providers and their patients. 

It is already embedded across a rapidly expanding global network that includes 1.7 million patients in more than 160 primary care sites in the UK, along with two million patients from a large US health system available from early next year.

Automate clinical study process

As per the company claims, the medical research studies can cost millions of pounds and up to 80% of these costs are associated with manual processes delegated to healthcare providers. In this case, uMed helps to eradicate the cost involved meanwhile safeguarding data.

The research technology company automates the clinical study process, creating regulatory quality patient registries that combine electronic health data with structured data captured from each patient including genomic and biomarker samples. 

Dr Wilson says: “Our technology can support healthcare providers in finding appropriate patients to participate in medical research including large scale patient registries which usually demands laborious, manual processes on top of their already complex and heavy workloads.

 “As our technology is uniquely able to reach back compliantly from the Electronic Health Record (EHR) to the patients, the process for building research registries can be heavily automated. It means clinicians can focus on patient care, while patients are allowed to participate in many more studies from home with full transparency over use of their health records.”

Christoph Ruedig, Partner at AlbionVC, comments: “AlbionVC has been investing in digital health for more than 10 years. We believe the next generation of healthcare disruptors are companies that can harness the power of that data to help improve healthcare. uMed has developed a powerful platform that can link some of the richest sources of healthcare data and drive a step change in how clinical and real-world research is conducted. We have been impressed by the company and its vision, and we are excited to support them as they enter the next stage of growth.”